Forma

The HME vs Spray Drying Debate Is Usually Over Before It Starts



Why process selection may not be the most important decision.

The HME vs Spray Drying Debate Is Usually Over Before It Starts

One of the most common formulation discussions in drug development revolves around the choice between hot melt extrusion and spray drying. Teams spend months evaluating process feasibility, equipment availability, development timelines, manufacturing costs, and scale-up considerations. Entire formulation strategies are often built around selecting one technology over the other.

Yet, watching numerous programs progress through development over the years, the pattern is clear: these debates might be focused on the wrong variable.

The reality is that the eventual success or failure of an amorphous solid dispersion is often determined long before an extruder is turned on or a spray dryer is commissioned. While formulation scientists understandably spend considerable time evaluating process technologies, the scientific factors that most heavily influence outcomes are frequently established much earlier.

In many cases, the molecule has already made the decision.

Most Companies Think They're Solving a Manufacturing Problem

When a poorly soluble molecule enters development, the conversation often begins with process selection. Can the API tolerate the temperatures required for hot melt extrusion? Can it be dissolved and with stand solvent exposure during spray drying? Which platform is more scalable? Which technology will provide the fastest path to clinic?

These are important questions, but they are rarely the most important questions.

The scientific literature repeatedly points to the same underlying factors: drug-polymer miscibility, molecular mobility, glass transition behavior, crystallization tendency, and phase stability. These characteristics ultimately determine whether an amorphous system can be created and maintained. More importantly, they are properties of the molecule itself, not the equipment used to process it.

A compound with poor miscibility characteristics does not suddenly become miscible because it was processed through an extruder. Likewise, a molecule prone to phase separation remains prone to phase separation regardless of whether the amorphous phase was generated through spray drying or hot melt extrusion. The process can influence the system, but it rarely overrides the underlying physical chemistry.

This distinction matters because manufacturing technologies are often evaluated as though they are solving the root problem. In reality, they are frequently asked to manage

consequences of the molecule's inherent behavior. Understanding that behavior early is often more valuable than optimizing a process later.

Generating Supersaturation Is Only the Beginning

Many formulation programs celebrate early dissolution results. For good reason. Poorly soluble compounds can exhibit dramatic improvements in dissolution when formulated as amorphous solid dispersions, and those results often create confidence that a bioavailability challenge has been solved.

The problem is that dissolution is usually the first hurdle, not the last.

Creating supersaturation is relatively straightforward. Maintaining it is considerably harder. Once the drug enters solution, the formulation begins fighting a thermodynamic battle that it is ultimately destined to lose. The molecule wants to return to its lower-energy crystalline state, and the role of the formulation scientist is to delay that process long enough for meaningful absorption to occur.

This is one reason polymer selection frequently proves more important than manufacturing technology. The polymer is not simply carrying the drug. It is actively influencing nucleation, crystal growth, molecular mobility, and precipitation kinetics. A well-designed system can suppress crystallization long enough to generate a meaningful pharmacokinetic benefit. A poorly designed system may generate impressive dissolution data only to lose that advantage moments later as precipitation occurs.

The highest-performing formulations are not always those that generate the largest concentration spike in a dissolution vessel. In many cases, they are the formulations that maintain a stable supersaturated state for the longest period of time. A lower peak concentration sustained over an extended period may ultimately create greater absorption than a dramatic concentration spike followed by rapid precipitation.

This distinction becomes increasingly important as molecules become more challenging and development programs become more ambitious. The goal is not simply to dissolve the drug. The goal is to keep it dissolved long enough for the patient to benefit.

Commercial Reality Changes Everything

Many amorphous solid dispersion programs look successful at low drug loadings.

The real challenge begins when commercial requirements enter the discussion.

Dose requirements increase. Drug loading targets increase. Stability margins narrow. More polymer may be required to maintain physical stability. Tablet weights begin to grow.

Manufacturing complexity increases. What initially appeared to be a straightforward formulation challenge gradually evolves into a product design challenge.

This is where many development programs encounter their most difficult decisions.

A formulation that performs exceptionally well at low drug loading may become increasingly impractical as dose requirements increase. Maintaining the amorphous state often requires additional stabilizing polymer, but there are limits to how much polymer can be incorporated before tablet size, manufacturability, and patient acceptance become concerns.

At this stage, the conversation shifts from formulation success to product success.

Scientists are no longer asking whether a formulation improves dissolution. They are asking whether the formulation can support a commercially viable medicine. Can it achieve the required dose? Can it maintain stability throughout shelf life? Can it be manufactured reproducibly at scale? Can it be converted into a dosage form that patients will actually take?

These questions often prove more important than the initial dissolution profile that generated excitement during early development.

The Molecule Usually Makes the Decision First

None of this suggests that the choice between spray drying and hot melt extrusion is unimportant.

Both technologies have enabled successful commercial products and both offer meaningful advantages. Hot melt extrusion can provide excellent downstream manufacturability, continuous processing, and dense particle characteristics. Spray drying often offers greater flexibility for thermally sensitive compounds and complex drug-polymer systems. Both deserve an important place in the formulation scientist's toolkit.

The mistake is assuming that the technology itself is the primary driver of success.

The most successful formulation teams are rarely attached to a particular platform. Instead, they focus on understanding molecular behavior. They study miscibility, crystallization risk, phase behavior, molecular mobility, precipitation kinetics, and stability before making technology decisions. By the time they begin evaluating manufacturing approaches, they already have a strong understanding of what the molecule is likely to tolerate and what risks must be managed.

The industry often treats manufacturing technology as the primary decision point in formulation development. The literature suggests otherwise. More often than not, the outcome was heavily influenced by the molecule's physical chemistry from the very beginning. Manufacturing technology can improve the odds, optimize the process, and help overcome obstacles. What it rarely does is change the fundamental nature of the system.

That is why the best formulation scientists are rarely asking whether a compound should be spray dried or hot melt extruded.

They are asking whether the molecule can support a robust amorphous system at the required drug loading, stability target, and commercial dose.

Once that question is answered, the technology decision often becomes much clearer.

In many cases, by the time the spray drying versus hot melt extrusion discussion begins, the answer has already been written into the chemistry.

About Forma

Forma Life Sciences is a U.S. based contract development and manufacturing organization (CDMO) specializing in oral solid dosage formulation development, clinical manufacturing, and commercial drug product manufacturing. Headquartered in Irvine, California, Forma operates two cGMP facilities totaling more than 100,000 square feet and 27 GMP manufacturing suites, with capacity to produce over two billion tablet and capsule units annually. The company supports pharmaceutical and biotechnology partners from early clinical development through commercial scale production and offers expertise in spray-dried dispersion, amorphous solid dispersion systems, fluid bed granulation, and modified-release formulation technologies.